Wednesday, July 8, 2026

pharma · Atopic Dermatitis Eczema · Plaque Psoriasis · ARQT

Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc is a pharma organization headquartered in Westlake Village, USA. It trades on NYSE under ticker ARQT. Primary therapeutic focus areas include Atopic Dermatitis Eczema, Plaque Psoriasis, Chron

2945 Townsgate Rd, Westlake Village, California 91361, US HQ
2016 Founded
427 Employees
Public company Type
ARQT · NYSE Ticker
Company details
Status
Public
HQ
2945 Townsgate Rd, Westlake Village, California 91361, US
Founded
2016
Employees
427
Programs
27
Drugs
3
Patents
30
Clinical program

Roflumilast Cream 0.05%

Phase 2 · small molecule · Atopic Dermatitis

Roflumilast Cream 0.05% for Atopic Dermatitis is a Phase 2 program (small_molecule) at Arcutis Biotherapeutics with 1 ClinicalTrials.gov record(s).

← All Arcutis Biotherapeutics projects Phase 2 small molecule completed

Internal code ARQ-151-212

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Arcutis Biotherapeutics
Phase
Phase 2
Modality
small_molecule
Indication
Atopic Dermatitis
Status
completed
Trials
1